Enlivex Therapeutics Releases Interim Data Readout From Phase I/II AllocetraTM Trial Showing; Three-Month Readout Showed Avg. Pain Reduciotn Of 64%, 33% Of Patients Reported Pain Resolution, 89% Of Patients Did Not Proceed With Knee Replacement Surgery
Enlivex Therapeutics Releases Interim Data Readout From Phase I/II AllocetraTM Trial Showing; Three-Month Readout Showed Avg. Pain Reduciotn Of 64%, 33% Of Patients Reported Pain Resolution, 89% Of Patients Did Not Proceed With Knee Replacement Surgery
enlivex therapeutics發佈一/二期allocetraTM試驗的中期數據，顯示：三個月的數據顯示平均疼痛減輕64%，33%的受試者報告疼痛緩解，89%的受試者沒有進行膝關節置換手術。
Enlivex Therapeutics Releases Interim Data Readout From Phase I/II AllocetraTM Trial Showing; Three-Month Readout Showed Avg. Pain Reduciotn Of 64%, 33% Of Patients Reported Pain Resolution, 89% Of Patients Did Not Proceed With Knee Replacement Surgery
enlivex therapeutics發佈一/二期allocetraTM試驗的中期數據，顯示：三個月的數據顯示平均疼痛減輕64%，33%的受試者報告疼痛緩解，89%的受試者沒有進行膝關節置換手術。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。